Physician profile
Tawfik N Chami
NPI 1730198052
$20,986.00
in general payments reported to CMS, 2019-2025
48 companies · $5,446 in 2025
The $5,446 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,347 · 2020: $5,241 · 2021: $471 · 2022: $1,943 · 2023: $3,171 · 2024: $2,368 · 2025: $5,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,346 · Travel and Lodging: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,345.73 |
| Travel and Lodging | $1,638.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,139.79 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Intercept Pharmaceuticals, INC. | $4,818.14 | 2019-2025 | Ocaliva |
| Genentech, INC. | $2,301.17 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,838.35 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $1,058.33 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $953.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $602.62 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $415.29 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $289.45 | 2019-2025 | Rebyota |
| Shionogi INC | $247.72 | 2019 | |
| Gilead Sciences, INC. | $227.62 | 2019-2025 | |
| Romark Laboratories, Lc | $216.12 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $209.87 | 2020-2025 | Linzess |
| Nestle Healthcare Nutrition INC. | $178.98 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $178.54 | 2024-2025 | Zenpep |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $174.16 | 2025 | Iqirvo |
| Pharming Healthcare, INC. | $171.60 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $169.65 | 2024-2025 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $164.16 | 2023-2025 | Fujifilm |
| Celltrion USA INC. | $150.55 | 2025 | Zymfentra, Vegzelma |
| Myriad Women'S Health, INC. | $145.55 | 2023 | Myrisk |
| Redhill Biopharma INC. | $139.10 | 2022-2024 | Talicia, Aemcolo |
| Ardelyx, INC. | $127.97 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $126.56 | 2023-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $124.95 | 2023 | Terlivaz |
| Madrigal Pharmaceuticals | $112.77 | 2025 | Rezdiffra |
| Lilly USA, LLC | $111.07 | 2024-2025 | Omvoh |
| Allergan, INC. | $101.38 | 2019-2020 | |
| Novo Nordisk INC | $62.90 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $58.47 | 2019-2023 | Injectafer |
| Amgen INC. | $49.82 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $49.64 | 2019-2022 | |
| Braintree Laboratories, INC. | $46.59 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $42.64 | 2022 | |
| Boston Scientific Corporation | $41.03 | 2019-2023 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $28.14 | 2025 | Givlaari |
| Dova Pharmaceuticals | $27.51 | 2019 | |
| Genzyme Corporation | $25.48 | 2022 | |
| Organon LLC | $16.08 | 2024 | |
| Exact Sciences Corporation | $15.83 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $14.91 | 2022 | |
| Covidien Lp | $12.27 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tawfik Chami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.